Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Selumetinib for NF1-PN in Chinese Children
NCT06763315Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selumetinib in plexiform neurofibroma (PN) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Change in tumor volume of plexiform neurofibromas. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT06763315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763315.